Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »
Feb 15, 2012 (Vol. 32, No. 4)

Molecular Diagnostic Alliances Increasingly the Norm

  • While molecular diagnostics may never completely replace “turn and cough,” it continues to gain prominence—from the companion diagnostics used to separate out potential responders to a specialty drug, to establishing a faster, more sensitive test for something as prevalent as tuberculosis. Opportunities for all stakeholders abound in developed and developing countries alike, as do the pitfalls associated with trying to take advantage of them. New markets emerge, regulations evolve, and technologies try to keep pace—sometimes by becoming less intense.

    CHI’s “Molecular Med Tri-Con 2012” conference will provide the opportunity for players to discuss the issues and garner insights from one another.

    Many drugs are coming through the pipeline paired with biomarkers. As these come to fruition over the next few years, drug companies need ways of testing for these markers—whether it’s by organically growing or acquiring a diagnostics arm, or by forming collaborations or partnerships with a diagnostics firm interested in creating a companion diagnostic.

    “People need these drugs, and pharma is not going to walk away from millions or billions of dollars in investments because they can’t figure out an assay,” says Mya Thomae, CEO of Myraqa, a California-based consultancy.

    While diagnostics companies may have great technology, they may not have ever had to go through an FDA clearance or approval. Companion diagnostics tends to be held to a higher level of regulatory scrutiny than other types of assays.

    They need to be able to put their best foot forward to show that they’re up to the task—“they have a plan for quality systems, they’re putting in the right infrastructure to support a regulated product,” Thomae points out. “So they can show a pharma company when they come in to do their due diligence on the partnership that they’re ready to go.”

    Part of this is realizing that the drug company will be aiming for a particular FDA approval date, and that the diagnostic company has to be prepared to file its application alongside the drug’s application and be ready when the drug is ready for approval. They need to be “working in lock-step, to make sure the assay is correct, it’s ready in time for clinical trials, and the other regulatory work they need to do is ready to go,” she warns. Otherwise, they could delay the drug getting to market.

    Companies also need to realize that while it’s in pharma’s interest to have tests as widely available and inexpensive as possible—especially if they’re required for treatment to be prescribed—that is generally not the case for the diagnostics companies.

    A drug company may help support development and clinical testing, but it will be up to the diagnostics company to make sure they’re doing things efficiently from a cost-of-goods perspective so that the test is profitable, explains Thomae. “This is a fundamental challenge, and one of the reasons that companion diagnostics have taken a while to make it to market.”

  • A New Paradigm

    It’s not just reimbursement issues that separate drug manufacturers from diagnostics companies. The advent of targeted therapeutics is a “direct challenge to the business models” of these two players, says Joseph Ferrara of Boston Healthcare Associates.

    “Innovators need to address a complex mix of value perspectives from stakeholders”—including patients, hospitals and physicians, regulators, and payers—and he is eager to facilitate a dialogue that may ultimately answer how the new personalized medicine paradigm will change companies’ approaches to innovation and commercialization.

    Assuming that they have already examined alignment of product development and manufacturing (as they normally would), Ferrara proposed that innovators consider five core commercialization factors. These, he says, are what BHA would ask clients when helping them develop their business model approach.

    First, what evidence might be needed beyond regulatory approval requirements and launch to achieve market acceptance? Demonstrating quality of the testing, and showing that the test could be conducted with minimal lab-to-lab variability, for example, could have an impact on the utility of the drug.

    Second is the logistics of distribution. Is the aim for the drug and test to be globally available, with multiple labs in each country? Or, if there will only be a small number of tests conducted, can a single lab do them all? Local regulatory requirements, too, need to be taken into consideration—for example, does a given country allow export of tissue samples?

    Third, because the test is in essence a gatekeeper for the drug’s acceptance, what pathways and policy restrictions to test access are payers likely to impose?

    The fourth factor centers around questions of financial risk for optimizing access to the drug, and what the likely payment outcomes might be. Take the case of a test costing twice as much to run (or that a lab is willing to accept) than what a payer is willing to reimburse under the current system, yet that test is essential for prescribing a treatment regimen. “Who makes up that difference?” asks Ferrara, “and what do the stakeholders need to do about it to address that gap?”

    His fifth and overarching theme involves innovator company organization and infrastructure: “Do the players have the people, the content, and the resources needed to optimize a very targeted medicine?” The answer remains to be seen, he says, explaining that the factors involved in this nascent field are just beginning to emerge.

Related content

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »